68Ga/177Lu诊疗一体化概念在前列腺特异性膜抗原靶向治疗去势抵抗性前列腺癌中的应用:SUVmax值与吸收剂量估算的相关性
10例连续入组的转移性去势抵抗性前列腺癌(mCRPC)患者接受177Lu-PSMA617治疗,基于68Ga-PSMA-HBED-CC PET/CT显示广泛且进展的肿瘤负荷入选。每周期静脉给药6.1 ± 0.3 GBq(范围5.4-6.5 GBq),间隔9 ± 1周;剂量学显示骨、淋巴结及肝转移灶肿瘤剂量较高,组织/器官剂量可接受。3例部分缓解、3例混合缓解、1例稳定、3例进展;骨骼、淋巴结、内脏及原发灶病灶的SUVmax值在2和3周期后下降(p < 0.05)。
要点
- 177Lu-PSMA617剂量学显示骨转移灶3.4 ± 1.9 Gy/GBq、淋巴结转移灶2.6 ± 0.4 Gy/GBq、肝转移灶2.4 ± 0.8 Gy/GBq。
- 68Ga-PSMA-HBED-CC平均SUVmax值从治疗前20.2降至2周期后15.0和3周期后11.5(p < 0.05)。
- 3例部分缓解、3例混合缓解、1例稳定、3例进展。
核心结论
- 由于个体差异大,177Lu-PSMA617治疗后必须进行剂量学评估以实现患者个体化方案。
- 作者建议在更大规模的前瞻性研究中应用更高活度和/或更短的治疗间隔。
研究设计与样本
- 连续入组10例mCRPC患者,基于68Ga-PSMA-HBED-CC PET/CT显示广泛且进展的肿瘤负荷选择接受177Lu-PSMA617治疗。
- 每周期177Lu-PSMA617静脉给药30分钟,活度6.1 ± 0.3 GBq(范围5.4-6.5 GBq),间隔9 ± 1周。
- 在第1周期剂量学评估及2和3周期治疗后进行再分期(68Ga-PSMA-HBED-CC和18F-NaF PET/CT),并与177Lu-PSMA617 24小时全身扫描及增强双期CT比较。
- 详细比较SUVmax值与肿瘤吸收剂量。
主要发现
- 177Lu-PSMA617剂量学显示骨转移灶肿瘤剂量3.4 ± 1.9 Gy/GBq(范围1.1-7.2 Gy/GBq),淋巴结转移灶2.6 ± 0.4 Gy/GBq(范围2.3-2.9 Gy/GBq),肝转移灶2.4 ± 0.8 Gy/GBq(范围1.7-3.3 Gy/GBq)。
- 计划治疗活度18 ± 0.3 GBq时,所有患者的组织/器官剂量可接受。
- 疗效:3例部分缓解、3例混合缓解、1例稳定、3例进展。
- 177Lu-PSMA617和68Ga-PSMA-HBED-CC摄取下降(平均SUVmax值治疗前20.2、2周期后15.0、3周期后11.5,p < 0.05),见于41/54个骨骼病灶、12/13个淋巴结转移灶、3/5个内脏转移灶和4/4个原发前列腺癌病灶。
关键数值与推荐
- 骨转移灶肿瘤剂量3.4 ± 1.9 Gy/GBq(范围1.1-7.2 Gy/GBq)。
- 淋巴结转移灶肿瘤剂量2.6 ± 0.4 Gy/GBq(范围2.3-2.9 Gy/GBq)。
- 肝转移灶肿瘤剂量2.4 ± 0.8 Gy/GBq(范围1.7-3.3 Gy/GBq)。
- 计划治疗活度18 ± 0.3 GBq时组织/器官剂量可接受。
- 平均SUVmax值治疗前20.2、2周期后15.0、3周期后11.5(p < 0.05)。
临床怎么用
- 177Lu-PSMA617治疗后应进行剂量学评估以实现患者个体化方案。
- 作者建议在更大规模的前瞻性研究中应用更高活度和/或更短的治疗间隔。
局限性
- 由于个体差异大,剂量学评估是必要的(原文结论中提及substantial individual variance)。
- 作者建议在更大规模的前瞻性研究中应用更高活度和/或更短的治疗间隔(原文结论中提及larger prospective study)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A targeted theragnostic approach based on increased expression of prostate-specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Ten consecutive mCRPC patients were selected for 177Lu-PSMA617 therapy on the basis of PSMA-targeted 68Ga-PSMA-HBED-CC PET/CT diagnosis showing extensive and progressive tumour load. Following dosimetry along with the first therapy cycle restaging (68Ga-PSMA-HBED-CC and 18F-NaF PET/CT) was performed after 2 and 3 therapy cycles (each 6.1 ± 0.3 GBq, range 5.4-6.5 GBq) given intravenously over 30 minutes, 9 ± 1 weeks apart. PET/CT scans were compared to 177Lu-PSMA617 24-hour whole-body scans and contrast-enhanced dual-phase CT. Detailed comparison of SUVmax values and absorbed tumour doses was performed. RESULTS: 177Lu-PSMA617 dosimetry indicated high tumour doses for skeletal (3.4 ± 1.9 Gy/GBq; range 1.1-7.2 Gy/GBq), lymph node (2.6 ± 0.4 Gy/GBq; range 2.3-2.9 Gy/GBq) as well as liver (2.4 ± 0.8 Gy/GBq; range 1.7-3.3 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 18 ± 0.3 GBq. Three patients showed partial remission, three mixed response, one stable and three progressive disease. Decreased 177Lu-PSMA617 and 68Ga-PSMA-HBED-CC uptake (mean SUVmax values 20.2 before and 15.0 after 2 cycles and 11.5 after 3 cycles, p < 0.05) was found in 41/54 skeletal lesions, 12/13 lymph node metastases, 3/5 visceral metastases and 4/4 primary PC lesions. CONCLUSION: Due to substantial individual variance, dosimetry is mandatory for a patient-specific approach following 177Lu-PSMA617 therapy. Higher activities and/or shorter treatment intervals should be applied in a larger prospective study.
引用
- Scarpa L, Buxbaum S, Kendler D, et al. The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017. PMID: 28083690. doi:10.1007/s00259-016-3609-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。